191
Participants
Start Date
June 30, 2014
Primary Completion Date
October 31, 2015
Study Completion Date
February 29, 2016
Apremilast
Orally twice a day (BID)
Apremilast
Orally twice a day (BID)
Placebo
Orally twice a day (BID)
Placebo
Orally twice a day (BID)
NYU Department of Dermatology, New York
Mount Sinai Medical Center, New York
Virginia Clinical Research Inc, Norfolk
Emory Clinic, Atlanta
Advanced Medical Research, Atlanta
Renstar Medical Research, Ocala
Dermatology Specialists, PSC, Louisville
Northwestern Medicine Lake Forest Hospital, Lake Forest
Northwestern University Northwestern Medical Faculty Foundation, Chicago
Arizona Research Center, Phoenix
Dermatology Research Associates, Los Angeles
Bakersfield Dermatology and Skin Cancer Medical Group, Bakersfield
Dartmouth Hitchcock Medical Center, Lebanon
PMG Research of Winston-Salem LLC, Winston-Salem
Oregon Health and Science University, Portland
Chih-Ho Hong Medical, Inc., Surrey
Eastern Canada Cutaneous Research Associates Ltd, Halifax
Ultranova Skincare, Barrie
K. Papp Clinical Research, Waterloo
Innovaderm Research, Montreal
Centre Dermatologique du Quebec Metropolitain, Ste-Foy
Kokubu Abashiri Dermatology Clinic, Abashiri-shi, Hokkaido
Asanuma Dermatology Clinic, Chitose-shi, Hokkaido
Fukuoka University Hospital Dermatology, Fukuoka-shi, Fukuoka
Hatamoto Dermatology Clinic, Fukuoka-shi, Fukuoka
Tashiro Clinic, Iizuka-shi, Fukuoka
Kokubu Dermatology, Kitami-shi, Hokkaido
University Hospital, Kyoto Prefectural University of Medicine, Kyoto
Kyoto University Hospital, Kyoto
Sapporo Skin Clinic, Sapporo-shi, Hokkaido
NTT Medical Center Tokyo, Shinagawa-ku, Tokyo
Lead Sponsor
Amgen
INDUSTRY